Head-to-head evidence
Bictegravir vs Elvitegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir · Biktarvy
Marketed by Gilead Sciences
NCT02607956 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial in 657 treatment-naive HIV-1 adults, powered for non-inferiority with a 12% margin. The primary endpoint was the FDA snapshot proportion with HIV-1 RNA <50 copies/mL at Week 48, a clinical virologic endpoint. The pre-specified non-inferiority comparison was met: B/F/TAF 89.4% vs DTG+F/TAF 92.9%, difference -3.5 (95.002% CI -7.9 to 1.0), with the confidence interval entirely within the 12% margin; the superiority test was not significant.
Next expected readout: December 2026 · NCT06830668 (registry estimate)
Elvitegravir · Stribild / Genvoya (component)
Marketed by Gilead Sciences
NCT00708162 · Phase 3 · completed
This was a randomized, triple-blind (participant, care provider, investigator), double-dummy, active-controlled phase 3 trial in 724 treatment-experienced HIV patients, comparing elvitegravir with raltegravir, both given with an optimized background regimen. The primary endpoint, confirmed HIV-1 RNA <50 copies/mL at week 48, was met as a non-inferiority result: 59.0% with elvitegravir vs 57.8% with raltegravir, with the 95% confidence interval for the difference (-6.0 to 8.2) falling entirely within the prespecified 10% margin. The trial was adequately powered (planned 700 participants, 85% power for non-inferiority).
Next expected readout: March 2034 · NCT06337032 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir's landscape · Elvitegravir's landscape